Therapeutic co‐targeting of PSMD14 and glycolytic lactylation significantly suppresses tumor growth in patient‐derived xenograft models, suggesting a promising combinatorial strategy for pancreatic cancer treatment. Here, PSMD14 is linked to pancreatic neoplasm.